Recursion Pharmaceuticals

Recursion has established itself as a pioneer in AI drug discovery, with a decade of data generation and a pipeline now in clinical trials. The platform's key differentiators are its massive proprietary dataset (>50 petabytes) and the integration of phenomics, transcriptomics, and proteomics, which allows for a more holistic understanding of disease biology. The automated wet lab and BioHive-2 supercomputer give it a compute advantage that few others have. However, this is not a tool for individual researchers or small biotechs—it's a full-stack pharmaceutical company. If you're a large pharma looking to accelerate your pipeline or a partner with deep pockets, Recursion's platform can significantly reduce time and cost from target to IND. But if you need a standalone AI tool for small molecule design or data analysis, other platforms like Schrödinger or Insilico may offer more accessible entry points. The platform's reliance on proprietary data means you must collaborate with Recursion; there is no public software or API described. The clinical results are promising, but the ultimate validation—FDA approval—is still pending for most candidates. Overall, Recursion is for serious institutional players, not for tinkerers.

Recursion Pharmaceuticals leverages artificial intelligence and machine learning to decode biology and radically improve lives. Founded over a decade ago, the company pioneered the use of cellular imaging and AI to understand vast biological space, aiming to reduce the massive 90% failure rate of traditional drug discovery. The Recursion OS, their proprietary drug discovery and development platform, integrates one of the largest fit-for-purpose datasets—over 50 petabytes spanning phenomics, transcriptomics, proteomics, ADME, and de-identified patient data. This enables intelligent ML models to identify new targets and design optimized molecules, fueling a pipeline of potential first-in-class and best-in-class treatments for aggressive cancers and rare diseases. Key features include an automated wet lab using robotics and computer vision to capture millions of cell experiments weekly, and BioHive-2, biopharma's most powerful supercomputer built with NVIDIA. The company has demonstrated significant improvements in speed, efficiency, and reduced costs from hit identification to IND-enabling studies compared to traditional pharma. Recursion also engages in strategic partnerships with industry leaders, technology giants, and data partners to accelerate AI-drug discovery. Their pipeline covers oncology indications like advanced solid tumors, B-cell malignancies, and rare diseases such as familial adenomatous polyposis and hypophosphatasia. As a top AI drug discovery company, Recursion positions itself at the forefront of TechBio, combining data, models, and compute to deliver better medicines faster.